FULVESTRANT Sandoz 250 mg/5ml i.m. 2 ser pré 5 ml
7680656510028
CH-65651
L02BA03
07.16.2.
Reimbursement limitations:
FULVESTRANT
Traitements des patientes à la post-ménopause (ménopause naturelle ou induite) avec cancer du sein localement …
1 / 2
google
Details
- Product number
- 6565101
- CPT
- -
- Packaging group
- 2
- Unit
- Fertigspritze(n)
- Composition
- fulvestrantum 250 mg, ethanolum 96 per centum 500 mg, alcohol benzylicus 500 mg, benzylis benzoas 750 mg, ricini oleum virginale q.s. ad solutionem pro 5 ml corresp. ethanolum 12.7 % V/V.
Articles (1)
Fulvestrant Sandoz 250 mg/5 ml, Injektionslösung in einer Fertigspritze
Injektionslösung
2
Official Swissmedic V2 data
Additional information from the official database
Official medical documents
Detailed composition
| Substance | Quantity | Type | Category |
|---|---|---|---|
|
(N/A)
|
250.0 MG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
500.0 MG | Substance | HBESI |
|
(N/A)
|
500.0 MG | Substance | HBESI |
|
(N/A)
|
750.0 MG | Substance | HBESI |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
12.7 PVV | Substance | HBESI |
Reimbursement information
Public price
CHF 329.05
Specialties list
Yes
Generic
Yes
Reimbursement limitation
SL addition date:
01/08/2016
Authorization holder
Sandoz Pharmaceuticals AG
6343 Risch
Authorization information
- Swissmedic authorization number
- 65651
- Drug name
- Fulvestrant Sandoz, Injektionslösung in einer Fertigspritze
- Galenic form
- INLFS
- ATC Code
- L02BA03
- Authorization status
- Z
- Dispensation category
- B
- First authorization
- 23/10/2015
- Authorization expiration date
- 31/12/9999
- IT number
- 07.16.2.
- Domain
- Human medicine
Packaging details
- Description (FR)
- FULVESTRANT Sandoz 250 mg/5ml i.m. 2 ser pré 5 ml
- Description (DE)
- FULVESTRANT Sandoz 250 mg/5ml i.m. 2 Fertspr 5 ml
- Market launch
- 23/10/2015
- Narcotic (BTM)
- No